SJS Investment Consulting’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$69K Buy
1,025
+115
+13% +$7.66K 0.01% 318
2026
Q1
$57.1K Sell
910
-60
-6% -$4.18K 0.01% 328
2025
Q4
$64.4K Buy
970
+578
+147% +$37.4K 0.01% 278
2025
Q3
$26.4K Buy
392
+384
+4,800% +$30.4K ﹤0.01% 479
2025
Q2
$699 Buy
8
+5
+167% +$392 ﹤0.01% 985
2025
Q1
$205 Hold
3
﹤0.01% 1447
2024
Q4
$234 Sell
3
-3
-50% -$222 ﹤0.01% 1443
2024
Q3
$403 Sell
6
-6
-50% -$493 ﹤0.01% 1385
2024
Q2
$1.36K Buy
12
+6
+100% +$759 ﹤0.01% 901
2024
Q1
$833 Buy
6
+1
+20% +$126 ﹤0.01% 1107
2023
Q4
$621 Buy
5
+2
+67% +$204 ﹤0.01% 1167
2023
Q3
$280 Sell
3
-805
-100% -$90.7K ﹤0.01% 1391
2023
Q2
$104K Sell
808
-2
-0.2% -$242 0.03% 102
2023
Q1
$94.1K Hold
810
0.03% 111
2022
Q4
$91.7K Buy
810
+808
+40,400% +$88.7K 0.03% 117
2022
Q3
$0 Buy
+2
New +$169 ﹤0.01% 1164
2022
Q1
$30K Buy
228
+20
+10% +$2.19K 0.01% 238
2021
Q4
$28K Buy
+208
New +$29.9K 0.01% 227

Other funds holding DXCM

SJS Investment Consulting's DXCM Position: Q2 2026 in Review

SJS Investment Consulting increased its DexCom (DXCM) stake by 13% in Q2 2026, buying an estimated $7.66K and bringing the position to 1,025 shares worth $69K. The position accounts for 0.01% of the portfolio, ranked #318.

SJS Investment Consulting first reported a position in DXCM in Q4 2021 and has held it in 18 quarters since. The position peaked at $104K in Q2 2023. 292 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • SJS Investment Consulting held 1,025 shares of DexCom worth $69K as of Q2 2026.
  • SJS Investment Consulting bought 115 DexCom shares in Q2 2026, an estimated $7.66K.
  • DexCom made up 0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #318 holding.
  • SJS Investment Consulting first reported a position in DexCom in Q4 2021 and has held it in 18 quarters since.
  • SJS Investment Consulting's DexCom position peaked at $104K in Q2 2023.
  • 292 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.